Press release
Cancer Biomarker Market Grows at 4.7 Percent CAGR with Rising Demand for Early Detection and Non-Invasive Diagnostics
Cancer Biomarker Market
According to the latest research by InsightAce Analytic, the Global Cancer Biomarker Market is valued at US$ 27.3 Bn in 2023, and it is expected to reach US$ 38.9 Bn by 2031, with a CAGR of 4.7% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2563
Cancer biomarkers represent a broad spectrum of biological molecules, including genes, proteins, and other indicators, that offer valuable insights into the onset, progression, and behavior of cancer. These biomarkers are instrumental in enhancing the understanding of cancer pathophysiology and play a pivotal role in facilitating early diagnosis, prognostic assessments, and the formulation of targeted treatment strategies. Their integration into precision medicine is transforming oncology by enabling highly individualized therapeutic approaches.
The global cancer biomarker market is experiencing significant growth, driven by technological advancements in diagnostics and the increasing incidence of cancer worldwide. A heightened emphasis on early detection and real-time disease monitoring is further accelerating market expansion. Key contributing factors include growing investment in research and development, increased adoption of personalized medicine, and a rising demand for non-invasive diagnostic methods.
Moreover, the expanding use of companion diagnostics and targeted therapies is strengthening the market's trajectory. Nevertheless, the sector faces several challenges, including high development and validation costs, stringent regulatory approval processes, and the inherent complexity of cancer biology. Despite these obstacles, sustained innovation, strategic industry partnerships, and ongoing scientific research are expected to support the continued advancement and long-term growth of the cancer biomarker market.
List of Prominent Players in the Cancer Biomarker Market:
• Agilent
• ARUP Laboratories
• BioReference
• Foundation Medicine
• OncoDNA
• Q2 Solutions
• Thermo Fisher Scientific
• YuceBio
• Asper Biogene
• Caris Life Sciences
• CeGaT
• Genekor Medical
• Guardant Health
• Labcorp
• MedGenome
• NeoGenomics Laboratories
• Nonacus
• Oxford Gene Technology
• Personal Genome Diagnostics
• PhenoPath
• Positive Biosciences
• Quest Diagnostics
• Tempus
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02
Market Dynamics
Drivers:
The cancer biomarker market is witnessing strong growth, largely fueled by the expansion of research and development (R&D) initiatives. Ongoing investigations aimed at identifying biomarkers associated with treatment resistance-particularly through genomic analysis-are improving the ability to predict therapeutic outcomes and assess post-radiation prognoses. The increasing global burden of cancer, combined with heightened research activity, is a significant catalyst for market expansion. Furthermore, strategic product innovations and pipeline developments by leading industry stakeholders are accelerating market advancement. The rising focus on precision oncology has led to the development of advanced biomarker-based diagnostic tools, as healthcare systems increasingly adopt personalized medicine approaches to enhance cancer detection and treatment outcomes.
Challenges:
Despite the rising demand for early cancer detection and biomarker-based diagnostics, the absence of consistent and comprehensive reimbursement frameworks in certain developed countries poses a major barrier to market adoption. Additionally, the high costs associated with cancer diagnostics and therapeutic interventions-particularly in emerging markets-limit patient access and present financial constraints to widespread deployment of biomarker technologies.
Regional Trends:
North America is expected to retain its dominant position in the cancer biomarker market, supported by a high prevalence of chronic illnesses, rapid technological advancement, and a well-established healthcare infrastructure. Substantial investments in medical research and development further bolster the region's market leadership. Meanwhile, the Asia-Pacific region is anticipated to demonstrate significant growth, driven by strategic market entry initiatives from key global players and increasing regional healthcare investment. The expanding presence of prominent companies within Asia-Pacific presents strong opportunities for continued growth in the global cancer biomarker industry.
Recent Developments
• In November 2023, Agilent received FDA approval for PD-L1 IHC 22C3 pharmDx in gastric or gastroesophageal junction (GEJ) adenocarcinoma.
• In December 2022, QIAGEN received FDA approval for a companion diagnostic to Mirati Therapeutics' KRAZATI in non-small cell lung cancer.
• In November 2022, Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, acquired Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.
• In May 2022, Illumina introduced a new pan-cancer companion diagnostic to match patients with rare genetic mutations to targeted therapy.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2563
Segmentation of Cancer Biomarker Market-
Cancer Biomarker Market- By Type of Biomarkers
• HER2
• MET
• EGFR
• PD-L1
• NTRK
• ALK
• Novel Biomarkers
• Other Biomarkers
Cancer Biomarker Market- By Type of Cancer
• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Thyroid Cancer
• Bladder Cancer
• Melanoma
• Non-Hodgkins Lymphoma
• Endometrial Cancer
• Kidney Cancer
• Leukemia
• Others
Cancer Biomarker Market- By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/cancer-biomarker-market/2563
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cancer Biomarker Market Grows at 4.7 Percent CAGR with Rising Demand for Early Detection and Non-Invasive Diagnostics here
News-ID: 4075154 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Direct Primary Care Market Growth Fueled by Increased Adoption Among Employers a …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as part of their plans)), Region, Market Outlook And Industry Analysis 2034."
Global Direct Primary Care…
Coconut Shell Powder Market Survey Detailed Analysis and Forecast 2025-2034
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Coconut Shell Powder Market Size, Share & Trends Analysis Report By Mesh Size (80-100 Mesh, 200-300 Mesh), by Application (Insect Repellent, Activated Carbon, Extender and Filler, Absorbent, Others), by Sales Channel (Offline, Online)- Market Outlook And Industry Analysis 2034"
The coconut shell powder market is estimated to reach over USD 675.1 Mn by 2034, exhibiting a…
Oligonucleotide Therapy Market Growing at 18.6 Percent CAGR Driven by Personaliz …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Oligonucleotide Therapy Market - (By Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others), By End User (Hospitals, Research Institutes, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Oligonucleotide Therapy Market is valued at…
Radionuclide Drug Conjugates Market Top Players - Telix Pharmaceuticals Limited, …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Radionuclide Drug Conjugates (RDCs) Market Size, Share & Trends Analysis Report By Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma, Others)- Market Outlook And Industry Analysis 2031"
The Global Radionuclide Drug Conjugates (RDCs) Market is expected to grow with a CAGR…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview
Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports.
This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
This report focuses on top…
